Fairmount Funds Management LLC bought $12M of CBIO
director, owner at CRESCENT BIOPHARMA, INC.. 853,450 shares at an average of $14.50, traded Jul 16, 2026, filed Jul 20, 2026.
Score components
- +15RoleDirector
- +25Trade size$12.4M at market
- +6Relative to holdingsHoldings up 31%
- +8Price context44% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-085113, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | POpen-market purchase Ordinary Sharesindirect: By Fairmount Healthcare Fund II L.P. | +853,450 | $14.50 | $12M | 3,601,316 | Jul 20, 2026 |
| Jul 16, 2026 | POpen-market purchase Pre-Funded Warrant (Right to Buy)derivativeindirect: By Fairmount Healthcare Fund II L.P. | +525,897 | $14.50 | $7.6M | 2,294,037 | Jul 20, 2026 |
Related signals
Other insiders at CRESCENT BIOPHARMA, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | CRESCENT BIOPHARMA, INC. | Barbara Harlin Bispham See Remarks | $11k 620 shares | -3% | |
| 31Weak | CRESCENT BIOPHARMA, INC. | Joshua T Brumm Chief Executive Officer | $160k 9,447 shares | -3% | |
| 23Weak | CRESCENT BIOPHARMA, INC. | Jonathan McNeill President and COO | $77k 4,570 shares | -3% | |
| 17Weak | CRESCENT BIOPHARMA, INC. | Richard William Scalzo Chief Financial Officer | $10k 568 shares | -3% | |
| 10Weak | CRESCENT BIOPHARMA, INC. | Ellie Eunkyung Im Chief Medical Officer | $11k 623 shares | -3% | |
| 10Weak | CRESCENT BIOPHARMA, INC. | Jan Pinkas Chief Scientific Officer | $12k 658 shares | -3% | |
| 10Weak | CRESCENT BIOPHARMA, INC. | Ryan Lynch See Remarks | $4,296 240 shares | -2% | |
| 10Weak | CRESCENT BIOPHARMA, INC. | Barbara Harlin Bispham See Remarks | $22k 1,218 shares | -6% | |
| 47Moderate | CRESCENT BIOPHARMA, INC. | Joshua T Brumm Chief Executive Officer | $761k 42,305 shares | -13% | |
| 35Weak | CRESCENT BIOPHARMA, INC. | Jonathan McNeill President and COO | $370k 20,549 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.